Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects

Øvrum, Eivind; Holen, Einfrid Åm; Tangen, Geir; Brosstad, Frank; Abdelnoor, Michel; Ringdal, Mari-Anne L.; Øystese, Rolf; Istad, Reidar

doi:10.1016/0003-4975(95)00366-s

Cited by 110 publications

(61 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of CPB requires full heparinization of the blood, and an activated clotting time (ACT) /480 s has been accepted as a safe level. It has even been shown that this level can be reduced to ACT /250 s with the use of heparincoated CPB circuits without any increased thrombogenicity or fibrinolytic activity (5). Postoperatively heparin usually is reversed with protamine at a dose of 1 mg protamine per 100 International Units (IU) heparin, and usually antithrombotic or antiplatelet treatment is discontinued seven days before the operation (5).…”

mentioning

confidence: 99%

Antithrombotic- and anticoagulation regimens in OPCAB surgery. A Nordic survey

Hansen

Hughes

2005

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Antithrombotic- and anticoagulation regimens in OPCAB surgery. A Nordic survey

Hansen

Hughes

2005

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

show abstract

“…13,14 There is one randomized trial with 90 patients showing better postoperative outcomes with reduced ventilation times and haemorrhage in high-risk groups (Euroscore +6), using hyaluronan-based heparin-bonded circuits. 15 It is possible that, in an elective series like ours with routine aortic valve and CABG patients with short CPB and cross-clamp times, there is no evidence of significant The limitations of our study are as follows.…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of outcome data with regards to the use of Phisio®-, Bioline®- or Softline®-coated cardiopulmonary bypass circuits in cardiac surgery

et al. 2012

View full text Add to dashboard Cite

BACKGROUND: Numerous cardiopulmonary bypass circuits with various coatings designed to reduce the inflammatory response and to provide better hemocompatibility are available. The aim of this study was to compare the effect of phosphorylcholine-coated, albumin-heparin-coated and synthetic polymer-coated perfusion tubing systems on patient outcome. METHODS: We performed a retrospective database review of elective patients between January 1st 2010 and December 31st 2010. Demographics, preoperative, operative, postoperative data and follow-up were collected and statistically analysed. RE-SULTS: We identified 201 patients and formed three groups: Group 1 with phosphorylcholine coating (n=133), Group 2 with albumin-heparin coating (n=32) and Group 3 synthetic polymer coating (n=36). Mean age was 68±11years, additive Euroscore 5.8±2.7. In-hospital outcomes were comparable between the groups without statistically significant differences. The overall 30-day and 1-year late survival were 98.5% and 96.7±1.9%, respectively. CONCLUSIONS: Our findings suggest that in-hospital and followup outcomes are comparable in cardiac surgery patients after using either phosphorylcholine-coated, albumin-heparin-coated or synthetic polymer-coated circuits during cardiopulmonary bypass.

show abstract

“…15 With PCPS support, sternal closure is easily achieved with relatively sufficient decompression of both ventricles, and the peripheral cannulation allows for easy removal of the system. In our PCPS patients, the postoperative bleeding and blood components required were significantly less than in the LHB group, mainly because the sternum could be closed under PCPS support.…”

Section: Discussionmentioning

confidence: 99%